Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $491.78, which forecasts a 16.67% increase in the stock price over the next year. The lowest target is $405 and the highest is $575.

Price Target: $491.78 (+16.67%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$405	$491.78	$480	$575
Change	-3.92%	+16.67%	+13.87%	+36.41%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	May '25	Jun '25	Jul '25	Aug '25	Sep '25	Oct '25
Strong Buy	10	9	8	8	8	8
Buy	6	6	6	6	8	8
Hold	11	11	11	10	9	10
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	27	26	25	24	25	26

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Maintains $439 → $438	Hold	Maintains	$439 → $438	+3.91%	Oct 10, 2025
Jessica Fye JP Morgan	JP Morgan	Buy Maintains $517 → $530	Buy	Maintains	$517 → $530	+25.73%	Oct 8, 2025
Geoff Meacham Citigroup	Citigroup	Strong Buy Maintains $550 → $575	Strong Buy	Maintains	$550 → $575	+36.41%	Oct 2, 2025
David Risinger Leerink Partners	Leerink Partners	Hold → Buy Upgrades $458 → $456	Hold → Buy	Upgrades	$458 → $456	+8.18%	Sep 25, 2025
Liisa Bayko Evercore ISI Group	Evercore ISI Group	Buy Maintains $510 → $475	Buy	Maintains	$510 → $475	+12.68%	Sep 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.23B

Increased by 10.93%

from 11.02B

Revenue Next Year

13.39B

Increased by 9.55%

from 12.23B

EPS This Year

18.38

from -2.08

EPS Next Year

20.63

Increased by 12.24%

from 18.38

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	6.21B	7.57B	8.93B	9.87B	11.02B	12.23B	13.39B
Revenue Growth	49.08%	22.06%	17.91%	10.51%	11.66%	10.93%	9.55%
EPS	10.29	9.01	12.82	13.89	-2.08	18.38	20.63
EPS Growth	128.16%	-12.44%	42.29%	8.35%	-	-	12.24%
Forward PE	-	-	-	-	-	22.93	20.43
No. Analysts	-	-	-	-	-	35	33

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	12.7B	15.1B
Avg	12.2B	13.4B
Low	11.6B	11.7B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	15.6%	23.3%
Avg	10.9%	9.6%
Low	5.3%	-4.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	19.77	26.88
Avg	18.38	20.63
Low	16.63	17.61

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	46.2%
Avg	-	12.2%
Low	-	-4.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.